Boswellia Dosage: How Much AKBA-Standardized Extract (100–250 mg/day)
Educational summary — not medical advice. Boswellia is an adjunct for symptom relief in osteoarthritis, not a cure. If you have significant joint pain, see a clinician. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
The studied dose is an AKBA-standardized extract, not plain boswellia: roughly 100–250 mg/day, taken daily. 5-Loxin (30% AKBA) was studied at 100 and 250 mg/day and Aflapin (~20% AKBA) at 100 mg/day (Sengupta 2008; Vishal 2011). Onset was relatively fast — around 5–7 days, with VAS/Lequesne responding before full WOMAC. The critical caveat: a milligram total can't confirm a trial-grade product, because most labels don't disclose AKBA — only 4 of 13 we track do.
The key thing most people get wrong: the dose is AKBA-standardized extract
Boswellia's benefit for osteoarthritis comes from AKBA (acetyl-11-keto-β-boswellic acid), which reduces inflammatory signaling by inhibiting the 5-LOX enzyme. So the trials dosed in milligrams of an AKBA-standardized extract, not grams of plain boswellia. Because those extracts are concentrated for AKBA, the doses are modest: 5-Loxin at 100 and 250 mg/day (Sengupta 2008) and Aflapin at 100 mg/day (Vishal 2011). Notably, more isn't simply better: in a head-to-head trial, Aflapin (~20% AKBA) outperformed 5-Loxin (30% AKBA) at the same 100 mg dose (Sengupta 2010) — the researchers attributed this to Aflapin's oil fraction improving absorption (Sengupta 2011).
| Question | Answer |
|---|---|
| How much? | ~100–250 mg/day of an AKBA-standardized extract (5-Loxin 100–250 mg; Aflapin 100 mg) |
| How fast? | Onset ~5–7 days; VAS/Lequesne respond before full WOMAC change |
| Higher AKBA % = better? | Not necessarily — Aflapin (~20% AKBA) beat 5-Loxin (30%) at 100 mg (absorption/oil fraction) |
| What matters on the label? | A disclosed AKBA % or a named extract (5-Loxin/Aflapin/AprèsFlex/BOS-10), not the raw mg |
| Cure or adjunct? | Adjunct for OA symptom relief — it slows a degradation marker (MMP-3), not regeneration |
| Can I confirm it from the mg alone? | No — AKBA is almost never disclosed; the mg total doesn't tell you the active |
AKBA checker: is your boswellia trial-grade?
Enter your extract mg per serving and servings per day. If your label discloses an AKBA percentage, add it — most don't, which is the whole point. The checker shows your daily extract dose against the studied 100–250 mg range, and, if AKBA is disclosed, your daily AKBA in mg.
Where to find the number: look for an explicit AKBA % or a named extract — 5-Loxin (30% AKBA), Aflapin / AprèsFlex (~20% AKBA), or BOS-10 — on the Supplement Facts panel. If the label only says "1200 mg" or "65% boswellic acids," the AKBA is undisclosed: leave the AKBA field blank, and the result is the finding.
How to take it
- Target a disclosed AKBA-standardized extract in the ~100–250 mg/day range — the doses the trials used (Sengupta 2008; Vishal 2011).
- Give it about a week. Onset was around 5–7 days in the trials, with pain (VAS/Lequesne) improving before the full WOMAC composite.
- Prioritize a disclosed AKBA figure over a big milligram number. A named clinical extract (5-Loxin/Aflapin/AprèsFlex/BOS-10) is the only way to know you're getting the active — see AKBA vs boswellic acids.
- Expect mild GI at most, and treat it as an adjunct. Boswellia's trial side-effect profile was mild (mostly minor GI); it's for symptom relief alongside your clinician's plan, not a replacement for it.
The AKBA-standardized pick
The honest picks here are the 4 products that disclose an AKBA % or a named clinical extract — useful precisely because you can match them to the trials. The cheapest per serving is below; full ranking on best boswellia.
Discloses AprèsFlex, 20% AKBA — a branded, trial-relevant extract — at 100 mg per serving. The lowest cost per serving in the AKBA tier, at $0.28/serving.
As an Amazon Associate we earn from qualifying purchases. Ranked by AKBA disclosure, never commissions.
Frequently asked questions
How much boswellia should I take per day?
Roughly 100–250 mg/day of an AKBA-standardized extract (5-Loxin 100–250 mg; Aflapin 100 mg). Because the extract is concentrated for AKBA, the mg total is modest — a plain "1200 mg" of undisclosed boswellia isn't the same.
How fast does it work?
Around 5–7 days in the trials, with VAS/Lequesne pain scales responding before full WOMAC (Sengupta 2008, day-7; Vishal 2011, day-5). It's fast for a botanical, but it's symptom relief, not reversal.
Why can't the milligrams tell me if it's trial-grade?
Because mg doesn't tell you AKBA, and commercial AKBA ranges from 3.83% down to 0.03% (Beghelli 2017). You need a disclosed AKBA % or a named extract — only 4 of 13 products we track disclose it.
Is more boswellia better?
No. A bigger mg number isn't proportional to AKBA, and Aflapin (~20% AKBA) beat 5-Loxin (30%) at the same 100 mg dose (Sengupta 2010) thanks to better absorption. Aim for a disclosed AKBA-standardized extract in range.
Does boswellia have side effects, and who should be cautious?
It's generally well tolerated; the main reports are mild GI effects like acidity or nausea. As a theoretical precaution, people taking anticoagulants or immunosuppressant medications should be cautious, and it's an adjunct for symptom relief, not a cure. Talk to your clinician before starting it if you take medications or have a health condition.
Related
- AKBA vs boswellic acids — why the "65%" number isn't the active
- Best boswellia — ranked by disclosure tier, then cost per serving
- Boswellia for osteoarthritis — the honest, fast-onset evidence
Sources
- Sengupta K, et al. "A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee." Arthritis Res Ther. 2008. PMID: 18667054 (100 and 250 mg/day; day-7 onset).
- Vishal AA, et al. "A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin in subjects with osteoarthritis of knee." Int J Med Sci. 2011. PMID: 22022214 (Aflapin 100 mg/day; day-5 onset).
- Sengupta K, et al. "Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study." Int J Med Sci. 2010. PMID: 21060724 (Aflapin outperformed 5-Loxin).
- Sengupta K, et al. "Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract." Mol Cell Biochem. 2011. PMID: 21479939 (why ~20% AKBA can beat 30%).
- Full product dataset: /boswellia/cost-by-brand.json (CC BY 4.0).